Abstract:In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01488?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01488</a>.Binding affinities of 13ac with 365 protein kinases;1H NMR, 13C NMR, MS/MS, and HPLC spectra of compound 13ac; routine blood test in normal mice; and effect of 13ac on mouse models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf">PDF</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> used for modeling docking in JAK2 of 13ac (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb">PDB</a>)PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> used for modeling docking in FLT3 of 18e (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb">PDB</a>)(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb">PDB</a>)Molecular formula strings of the prepared compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv">CSV</a>)This article has not yet been cited by other publications.

Design, Synthesis and Evaluation of Pyrrolo[2,3-D]pyrimidine-phenylamide Hybrids As Potent Janus Kinase 2 Inhibitors.

Design and Synthesis of Novel Pyrrolo[2,3-D]pyrimidine Derivatives As Potent JAK3 and SYK Dual Inhibitors

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.

Synthesis and JAK2 Inhibitory Activities of 4-Phenyl-pyrrolo[2, 3-D] Pyrimidine Derivatives

Discovery of Imidazopyrrolopyridines Derivatives As Novel and Selective Inhibitors of JAK2.

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

Design, synthesis and bioactivities of 4-(3-sulfonylbenzene) amino-6-formylpyrrole[2, 3-d] pyrimidine derivatives

Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1h)-pyrazole Derivatives As JAKs Inhibitors.

Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.

Design, Synthesis, and Pharmacological Evaluation of 4- or 6-Phenyl-pyrimidine Derivatives As Novel and Selective Janus Kinase 3 Inhibitors.

Identification of 4-(2-furanyl)pyrimidin-2-amines As Janus Kinase 2 Inhibitors.

N -(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.

Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors

Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors

In Vitro and in Vivo Evaluation of 6-Aminopyrazolyl-pyridine-3-carbonitriles As JAK2 Kinase Inhibitors.